Clinical trials
HIV-1-infection clinical trials
Below are recruiting hiv-1-infection clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06890988Recruiting
Dental team study to help end HIV epidemic
This trial tests if training dental teams (dentists, hygienists, assistants, navigators) can help end the HIV epidemic by offering HIV testing and prevention in dental visits. You may be able to join if you work in a dental practice that is part of this study.
New York, New YorkAges 18 years+ - NCT06880380RecruitingPhase 1
CAR-T cell therapy for functional HIV cure
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05652088Recruiting
Study gut immune tissue in HIV cure efforts
This study looks at how immune tissue in the gut may be involved in curing HIV. You may be asked to have two colonoscopies while on an HIV “cure-related” treatment, so researchers can collect tissue samples to understand what’s happening in your body.
New York, New YorkAges 18–75 - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT06648629Recruiting
Counseling to help HIV patients who drink too much
This study tests a counseling approach called Acceptance and Commitment Therapy (ACT) to help people living with HIV who drink at unhealthy levels reduce their drinking. If you're on HIV treatment and drink more than recommended, this program may help you build healthier habits.
Syracuse, New YorkAges 18 years+ - NCT06554717RecruitingPhase 2
Tesamorelin and exercise for physical function in HIV
This study tests whether adding tesamorelin to an exercise program helps older adults with HIV improve their physical function and reduce belly fat. It is designed for people who are mostly sedentary and show early signs of frailty.
Aurora, ColoradoAges 50–80 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Los Angeles, CaliforniaAges Up to 3 days - NCT06337032RecruitingPhase 4
Continued access to HIV treatment for children and teens
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
Buenos AiresAges 1 month+ - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT05973825Recruiting
HIV blood study to study immune responses over many years
This study looks at how the immune system and HIV behave in people on long-term HIV treatment (ART), using blood samples that will be stored for future tests for up to 20 years. It may help researchers understand how well treatment is controlling HIV and improve future care.
Ghent, Oost-VlaanderenAges 18–80 - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT05668026RecruitingPhase 1/Phase 2
Venetoclax to shrink HIV reservoir in people on stable ART
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
Melbourne, MelbourneAges 18–65 - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65 - NCT05143307Enrolling by invitationPhase 1
Follow-up study for adults who received EBT-101 for HIV
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
San Francisco, CaliforniaAges 18 years+ - NCT04160455Recruiting
Study of GALIG proteins in adults with HIV on or off treatment
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
OrléansAges 18 years+ - NCT04883255RecruitingEarly Phase 1
Study cannabis effects on brain function in adults with HIV
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
San Diego, CaliforniaAges 18–65 - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT05728996Recruiting
Study of early HIV to guide future care
This study follows people with a very recent HIV infection and collects blood and other samples to learn more about the infection soon after it starts. It may help researchers better understand early HIV and improve future treatments.
Amsterdam, North HollandAges 18 years+ - NCT07293559Recruiting
Understanding infant feeding choices in women with HIV
This study looks at how women with HIV decide whether to breastfeed, and what support they get from healthcare providers and family. It aims to learn about their experiences and needs.
Los Angeles, CaliforniaAges Any age - NCT03729752RecruitingPhase 1
PET scan to study an HIV-fighting antibody in the body
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
San Francisco, CaliforniaAges 18 years+ - NCT07643948Recruiting
How HIV Treatment Changes Affect Drug Resistance
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
Hong Kong, Hong KongAges 18 years+ - NCT06484335RecruitingPhase 1
HIV vaccine study with treatment pause for Thai adults
This study tests whether adding an experimental vaccine can help your immune system control HIV during a temporary break from your antiretroviral therapy (ART). If you have been on ART since shortly after infection with a suppressed viral load, this trial could help you understand if a 'functional cure' is possible.
Pathum Wan, BangkokAges 18–60 - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv-1-infection?
- Yes. Clin2 currently lists 86 recruiting hiv-1-infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1-infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1-infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.